Company profile
LAKEFRONT BIOTHERAPEUTICS NV
NASDAQ:LKFTBiotechnology: Pharmaceutical Preparations
Drug pipeline (16)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ZIRITAXESTAT | phase3 | — | 8 | completed, terminated |
| ALDUMASTAT | phase2 | — | 3 | no active trials |
| CADEFRECITINIB | phase2 | — | 8 | no active trials |
| FILGOTINIB HYDROCHLORIDE | phase2 | — | 11 | no active trials |
| GALICAFTOR | phase2 | — | 8 | completed, terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (115)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03725852 | phase2 | completed | 2018-09-27 | 2020-07-21 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1205 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) |
| NCT03733444 | phase3 | terminated | 2018-11-05 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03798366 | phase2 | completed | 2019-01-14 | 2020-05-21 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis |
| NCT03711162 | phase3 | terminated | 2018-11-28 | 2021-03-30 | Lakefront Biotherapeutics NV | A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis (IPF) When Used Together With Standard of Care |
| NCT03976648 | phase2 | terminated | 2019-07-18 | 2021-04-13 | Lakefront Biotherapeutics NV | A Clinical Study to Test Long Term Safety of GLPG1690 for Patients With Systemic Sclerosis |
FDA applications (0)
No records yet.